Physician profile
Jamison Jones
NPI 1598226698
$6,991.71
in general payments reported to CMS, 2019-2025
47 companies · $2,007 in 2025
The $2,007 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $36.73 · 2022: $550 · 2023: $2,254 · 2024: $2,143 · 2025: $2,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,405.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,064.05 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,022.75 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $847.52 | 2023-2025 | |
| Glaxosmithkline, LLC. | $601.47 | 2023-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Lilly USA, LLC | $569.84 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $277.44 | 2022-2025 | Belsomra, Gardasil 9, Steglatro |
| Antares Pharma, INC. | $188.65 | 2022-2023 | Xyosted, Tlando, Nocdurna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.78 | 2022-2025 | Jardiance |
| Amgen INC. | $174.02 | 2022-2025 | Otezla, Repatha, Otezla |
| Corcept Therapeutics | $166.99 | 2023-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $141.17 | 2022-2025 | |
| Inspire Medical Systems, INC. | $117.66 | 2024-2025 | Inspire |
| Novo Nordisk INC | $109.64 | 2022-2025 | Wegovy |
| Corium, LLC | $109.05 | 2022-2023 | Azstarys |
| Abbott Laboratories | $105.90 | 2024-2025 | Freestyle Libre 3 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamison Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.